K. Evan Thompson BS, PhD

Dr. Theraxen is a biotechnology company developing xeno (non-DNA/RNA) nucleic acids and nucleotides for therapeutic applications.The company is leveraging its platform technologies to select xenonucleic acid aptamers, catalysts, as well as nucleotide analogs, to target infectious diseases, with a focus on antiviral therapeutics. Thismulti-faceted approach to development provides the unique opportunity for multiple “shots on goal” with different mechanisms of action,enabling the selection of the most promising candidates and combinationsand significantly improving the chances of clinical success. The company’s leadership team is Drs. Evan Thompson, Philippe Marlière, and Piet Herdewijn. Dr. Thompson’s background is as a life science consultant, investor, and scientist.

He has worked with healthcare investors, private and public biotechnology companies, and life science service providers to identify programs with the highest potential and the keys for successful development.

Dr. Marlière is a scientist and serial entrepreneur. He is a leader in the fields of metabolic engineering and xenobiology, and a cofounder of several successful biotechnology companies including Heurisko (microorganism evolution) and Global Bioenergies (hydrocarbon biofuels). Dr. Herdewijn is a professor of medicinal chemistry at KU Leuven who has pioneered the field of XNA, as well as nucleotide analog and polynucleotide chemistry